SCHEMBL15701757

SCHEMBL15701757

CCOC(=O)c1cc(C(=O)O)ccc1-n1nc(C)c(Cl)c1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPC1 P48995 2/20 0.43
TRPC3 Q13507 2/20 0.43
STIM1 Q13586 2/20 0.43
ORAI1 Q96D31 2/20 0.43
STIM2 Q9P246 2/20 0.43
POLB P06746 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PDE4B Q07343 1/20 0.39
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 5/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
OPRM1 P35372 1/20 0.38
NR3C1 P04150 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15701756 0.88 MAPT (0.44) MEN1KMT2APDE4BALDH1A1KDM4E
SCHEMBL15701753 0.86 POLB (0.54) POLBMEN1KMT2APDE4BALDH1A1
SCHEMBL14060993 0.86 BCL2 (0.45) TRPC1TRPC3STIM1ORAI1STIM2
SCHEMBL15701758 0.77 BCL2 (0.59)
SCHEMBL14149711 0.75 BCL2 (0.43) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL14061142 0.75 BCL2 (0.45) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL15701748 0.73 MAPT (0.47) POLBMEN1KMT2APDE4BALDH1A1
SCHEMBL14061065 0.73 BCL2 (0.43) POLBMEN1KMT2APDE4BALDH1A1
SCHEMBL14061043 0.71 BCL2 (0.52)
SCHEMBL20502850 0.69 POLB (0.55) POLBMEN1KMT2APDE4BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 US disclosed
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 TRPC1 3654/4885TRPC3 3594/4885STIM1 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.